Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.

You may also be interested in...



Aduro Says End Of Janssen Collaborations “Not A Lethal Blow”

Both Janssen and Aduro gradually realized the Listeria technology platform was not delivering hoped-for results. Aduro will not continue the projects abandoned by Janssen, and will focus on its STING and APRIL programs going forward.

Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs

Novartis may be behind other big rivals that already have immuno-oncology therapies on the market but its top R&D scientists Alessandro Riva and Usman Azam say it can leap frog to a front position using its early IO pipeline and targeted cancer drugs.

Biopharma Quarterly Dealmaking Statistics, Q1 2015

Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS078357

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel